Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells
- PMID: 16361572
- PMCID: PMC3144933
- DOI: 10.1158/1078-0432.CCR-05-1728
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells
Abstract
Objective: Docetaxel causes cell death through induction of apoptosis; however, cell death characteristics for docetaxel have not yet been fully elucidated. We examined the role of focal adhesion kinase (FAK) cleavage in docetaxel-mediated apoptosis.
Methods: FAK degradation after treatment with docetaxel was determined in both taxane-sensitive (HeyA8 and SKOV3) and taxane-resistant (HeyA8-MDR and SKOV3-TR) ovarian cancer cell lines by Western blot analysis. Cell growth was determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. FAK-targeting small interfering RNA (siRNA) was used to decrease FAK expression. Apoptosis and caspase activity were determined using commercially available kits.
Results: SKOV3 and HeyA8 cell lines were both sensitive to docetaxel (IC50 levels, 1-6.2 nmol/L), whereas the SKOV3-TR and HeyA8-MDR cells were resistant (IC50>or=250 nmol/L for both). Docetaxel induced high rates of apoptosis in SKOV3 and HeyA8 cells (84% and 66% apoptosis, respectively) but minimal apoptosis (5-8%) in SKOV3-TR and HeyA8-MDR cells. Similarly, FAK was cleaved in SKOV3 and HeyA8 cells in response to docetaxel treatment but unchanged in the resistant cells. Caspase-3 and caspase-8 activity also increased significantly in docetaxel-treated SKOV3 and HeyA8 cells but not in the taxane-resistant cells. DEVD-fmk (caspase-3 blocker) was able to block both FAK cleavage and apoptosis mediated by docetaxel in SKOV3 and HeyA8 cells. FAK siRNA transfection resulted in 70% to 90% decrease in FAK levels in all cell lines within 72 hours. FAK silencing augmented docetaxel-mediated growth inhibition (5- to 8-fold increase) and apoptosis in both of the taxane-sensitive and taxane-resistant cell lines.
Conclusions: Docetaxel induces FAK cleavage, mediated through activation of caspase-3, in taxane-sensitive ovarian cancer cells but not in taxane-resistant cells. The absence of FAK degradation may contribute to cell survival in taxane-resistant cells. FAK silencing promotes the in vitro efficacy of docetaxel in both taxane-sensitive and taxane-resistant cell lines and may serve as a novel therapeutic approach.
Figures







Similar articles
-
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.Clin Cancer Res. 2006 Aug 15;12(16):4916-24. doi: 10.1158/1078-0432.CCR-06-0021. Clin Cancer Res. 2006. PMID: 16914580 Free PMC article.
-
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.Cancer Res. 2007 Nov 15;67(22):10976-83. doi: 10.1158/0008-5472.CAN-07-2667. Cancer Res. 2007. PMID: 18006843
-
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.J Natl Cancer Inst. 2011 Nov 2;103(21):1596-612. doi: 10.1093/jnci/djr372. Epub 2011 Sep 28. J Natl Cancer Inst. 2011. PMID: 21957230 Free PMC article.
-
Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.Curr Cancer Drug Targets. 2019;19(3):179-188. doi: 10.2174/1568009618666180706165222. Curr Cancer Drug Targets. 2019. PMID: 29984656 Review.
-
Docetaxel in ovarian cancer.Expert Opin Pharmacother. 2005 Dec;6(15):2719-26. doi: 10.1517/14656566.6.15.2719. Expert Opin Pharmacother. 2005. PMID: 16316310 Review.
Cited by
-
The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?J Exp Clin Cancer Res. 2022 Sep 16;41(1):276. doi: 10.1186/s13046-022-02484-1. J Exp Clin Cancer Res. 2022. PMID: 36114508 Free PMC article. Review.
-
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.Br J Cancer. 2012 May 22;106(11):1728-34. doi: 10.1038/bjc.2012.158. Epub 2012 Apr 24. Br J Cancer. 2012. PMID: 22531637 Free PMC article. Clinical Trial.
-
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.Molecules. 2021 Jul 13;26(14):4250. doi: 10.3390/molecules26144250. Molecules. 2021. PMID: 34299525 Free PMC article. Review.
-
Focal adhesion kinase is a phospho-regulated repressor of Rac and proliferation in human endothelial cells.Biol Open. 2012 Aug 15;1(8):723-30. doi: 10.1242/bio.20121008. Epub 2012 Jun 12. Biol Open. 2012. PMID: 23213465 Free PMC article.
-
FAK is involved in invasion and metastasis of hepatocellular carcinoma.Clin Exp Metastasis. 2010 Feb;27(2):71-82. doi: 10.1007/s10585-010-9306-3. Epub 2010 Feb 24. Clin Exp Metastasis. 2010. PMID: 20180147
References
-
- Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30. - PubMed
-
- McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. [comment] N Engl J Med. 1996;334:1–6. - PubMed
-
- Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998;55:5–30. - PubMed
-
- Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S. Preclinical evaluation of docetaxel (Taxotere) Semin Oncol. 1995;22:3–16. - PubMed
-
- Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 1996;56:816–25. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous